Publicaciones (22) Publicaciones de Irena Misiewicz Krzeminska

2022

  1. CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma

    Cancers, Vol. 14, Núm. 18

  2. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

    American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710

  3. Extracellular Vesicles in Multiple Myeloma—Cracking the Code to a Better Understanding of the Disease

    Cancers, Vol. 14, Núm. 22

  4. Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing

    Biomedicines, Vol. 10, Núm. 7

2021

  1. The crbn, cul4a and ddb1 expression predicts the response to immunomodulatory drugs and survival of multiple myeloma patients

    Journal of Clinical Medicine, Vol. 10, Núm. 12

2020

  1. Effect of graphene family materials on multiple myeloma and non-Hodgkin's lymphoma cell lines

    Materials, Vol. 13, Núm. 15, pp. 1-21

2019

  1. Factors regulating microRNA expression and function in multiple myeloma

    Non-coding RNA, Vol. 5, Núm. 1

  2. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background

    Blood Cancer Journal, Vol. 9, Núm. 12

2018

  1. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility

    Haematologica, Vol. 103, Núm. 5, pp. 880-889

2017

  1. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients

    Clinical and Translational Oncology, Vol. 19, Núm. 11, pp. 1350-1357

  2. Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma

    Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615

  3. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  4. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  5. The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

    Haematologica, Vol. 102, Núm. 12, pp. 2113-2124

2016

  1. Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients

    PLoS ONE, Vol. 11, Núm. 2

  2. Molecular mechanisms of p53 deregulation in cancer: An overview in multiple myeloma

    International Journal of Molecular Sciences, Vol. 17, Núm. 12

  3. Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma

    Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217

2015

  1. Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma

    Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, Vol. 1849, Núm. 3, pp. 353-366

  2. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL

    BMC Cancer, Vol. 15, Núm. 1

2013

  1. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication

    Haematologica, Vol. 98, Núm. 4, pp. 640-648